Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 23, 2024 (2 years ago)

Cloderm (clocortolone pivalate)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Cloderm (clocortolone pivalate) Cream, 0.1%, Rx Only, For Topical Use Only, Net Wt 45g, Manufactured for: EPI Health, LLC, Charleston, SC 29403, NDC 71403-804-90

Affected NDC 71403-0804-90

Compare with the code on your package — it is the most precise check available.

Recalling firm
EPI Health, LLC
NDC code
71403-804-90
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0473-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by EPI Health, LLC

All 2024 recalls
Class II · Moderate risk

minolira (minocycline hydrochloride)

CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Terminated cGMP deviation EPI Health, LLC NDC 71403-102-30 D-0475-2024
Class II · Moderate risk

minolira (minocycline hydrochloride)

CGMP Deviation: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

Terminated cGMP deviation EPI Health, LLC NDC 71403-101-30 D-0474-2024

Other cgmp deviation recalls from 2024

All cgmp deviation recalls
Class II · Moderate risk

Henry Schein

CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.

Terminated cGMP deviation Keystone Industries D-0148-2025